<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RAMIPRIL</span><br/>(ram'i-pril)<br/><span class="topboxtradename">Altace<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme (ace) inhibitor</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.25 mg, 2.5 mg, 5 mg, 10 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Reduces peripheral vascular resistance by inhibiting the formation of angiotensin II, a potent vasoconstrictor.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers BP. Inhibition of ACE also decreases serum aldosterone levels; reduces peripheral arterial resistance (afterload) and
         improves cardiac output as well as exercise tolerance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension, CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ramipril or any other ACE inhibitor, patients with history of angioneurotic edema; pregnancy (category
         D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function, surgery or anesthesia. Safety and effectiveness in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, CHF</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.55 mg q.d., may increase up to 20 mg/d in 12 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue diuretics 23 d before initiation of drug. Limit initial dose to 1.25 mg if diuretics cannot be discontinued.</li>
<li>Store at 15°30° C (59°86° F) and protect from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, fatigue, headache. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, eructation. <span class="typehead">Metabolic:</span> Hyperkalemia, hyponatremia. <span class="typehead"> Skin:</span> erythema, pruritus. <span class="typehead">Body as a Whole:</span> <span class="speceff-life">Angioedema</span>. <span class="typehead">Respiratory:</span> Cough. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">potassium-sparing diuretics</span> may increase risk of hyperkalemia. May, elevate, serum <b>lithium</b> levels, resulting in lithium toxicity. <span class="classification">nsaids</span> may attenuate antihypertensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 60% absorbed from GI tract. <span class="typehead">Onset:</span> 2 h. <span class="typehead">Peak:</span> 68 h. <span class="typehead">Duration:</span> Up to 24 h. <span class="typehead">Distribution:</span> Crosses placenta; not known if distributed into breast milk. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver to its active metabolite, ramiprilat. <span class="typehead">Elimination:</span> 4060% excreted in urine, 40% in feces. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP at time of peak effectiveness, 36 h after dosing and at end of dosing interval just before next dose.</li>
<li>Report diminished antihypertensive effect.</li>
<li>Monitor for first-dose hypotension, especially in salt- or volume-depleted persons.</li>
<li>Lab tests: Monitor BUN and serum creatinine periodically. Increases may necessitate dose reduction or discontinuation of drug.
            Monitor serum potassium values.
         </li>
<li>Observe for S&amp;S of hyperkalemia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug and report S&amp;S of angioedema to physician (e.g., swelling of face or extremities, difficulty breathing or
            swallowing).
         </li>
<li>Maintain adequate fluid intake and avoid potassium supplements or salt substitutes unless specifically prescribed by the physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>